Therapies for Rheumatoid Arthritis: Technologies and Global Markets

Report Scope

The current report will provide detailed information on therapies for rheumatoid arthritis (RA). This report analyzes the market trends of RA therapies, with the base year for the study set at 2024, estimated for 2025, and forecast between 2026 and 2030, including compound annual growth rate (CAGR) for the forecast period and regional markets. The report will highlight current and future market potential and provide a detailed analysis of the competitive environment as well as regulatory scenarios, drivers, restraints, and opportunities. The report also covers the market shares for key producers.

The market scope in this report is segmented into therapies, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), steroids/corticosteroids, biosimilars, and others. It also covers over-the-counter (OTC)- and prescription-based sales channels.

The report covers significant geographical regions: North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The regional segmentation will offer a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia, and India. For market estimates, data will be provided for 2024 as the base year, with forecasts for 2025 through 2030.

The report aims to:

  • Analyze RA therapy types.
  • Analyze global market size and segmentation.
  • Understand market constraints and drivers.
  • Provide detailed market forecasts for 2030.
  • Assess market shares, competitiveness, and industry structure.
  • Identify potential long-term impacts on the market for RA therapies.
Report Includes
  • 94 data tables and 51 additional tables
  • In-depth analysis of the global markets for rheumatoid arthritis (RA) treatment therapies
  • Analyses of global market trends, with revenue data for 2024, estimates for 2025, forecasts for 2026, and projected CAGRs through 2030
  • Estimates of the market’s current size and revenue prospects, accompanied by a market share analysis based on therapy type, sales channel and region
  • Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors
  • Insights derived from Porter’s Five Forces model, as well as global supply chain analysis
  • Discussion of the key marketed products and products in different stages of clinical development
  • An analysis of patents, and emerging trends and developments in patent activity
  • Overview of sustainability trends and ESG developments, with consumer attitudes, and the ESG scores and practices of leading companies
  • Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
  • Company profiles of major players within the industry, including AbbVie Inc., Pfizer Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Co., Amgen Inc., and F. Hoffmann-La Roche Ltd.

    Companies Mentioned

    Abbott
    Abbvie Inc.
    Amgen Inc.
    Bayer Ag
    Bristol-myers Squibb Co.
    F. Hoffmann-la Roche Ltd.
    Gilead Sciences Inc.
    Gsk Plc.
    Johnson & Johnson Services Inc.
    Lilly
    Pfizer Inc.
    Sanofi
    Swedish Orphan Biovitrum Ab
    Teva Pharmaceutical Industries Ltd.
    Viatris Inc.


Chapter 1 Executive Summary
Market Outlook
Scope Of Report
Market Summary
Chapter 2 Market Overview
Overview
Macroeconomic Factor Analysis
Impact Of U.S. Tariffs On The Pharmaceutical Industry
Aging Population
Geopolitical Risks, Trade Wars, And Supply Chain Disruptions
Increasing Healthcare Expenditures
Porter's Five Forces Analysis
Bargaining Power Of Buyers
Bargaining Power Of Suppliers
Potential For New Entrants
Threat Of Substitutes
Competitiveness In The Industry
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Increasing Biosimilars For Ra Treatment
Rising Cases Of Ra
Increasing Aging Population
Market Restraints
Loss Of Patent Exclusivity
Shortage Of Rheumatologists
Side Effects Of Ra Drugs
Market Opportunities
Technological Advances In Ra Therapies
Emerging Targeted Therapies
Increasing Inorganic Strategies Amongst Manufacturers
Chapter 4 Regulatory Landscape
Overview
The U.S.
Biologics
Biosimilars
Europe
Asia-pacific
Chapter 5 Emerging Technologies And Pipeline Analysis
Overview
Artificial Intelligence (Ai) And Machine Learning (Ml)
Stem Cell Therapy
Immunotherapy
Pipeline Analysis
Patent Analysis
Key Takeaways
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Market For Ra Therapies By Therapy Type
Key Takeaways
Disease-modifying Anti-rheumatic Drugs (Dmards)
Targeted Synthetic Dmards/Jak Inhibitors
Non-steroidal Anti-inflammatory Drugs (Nsaids)
Biosimilars
Steroids
Other Drugs
Global Ra Therapies By Sales Channel
Key Takeaways
Prescription Drugs
Over-the-counter (Otc) Drugs
Geographic Breakdown
Global Market For Ra Therapies, By Region
Key Takeaways
North America
Europe
Asia-pacific
Middle East And Africa (Mea)
South America
Chapter 7 Competitive Intelligence
Key Takeaways
Market Share Analysis
Company Share Analysis
Chapter 8 Sustainability In The Ra Therapies Market: An Esg Perspective
Introduction To Esg
Sustainability In The Market For Ra Therapies
Esg Perspective
Environmental Impact
Social Impact
Governance Impact
Esg Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Abbreviations
Sources
Company Profiles
Abbott
Abbvie Inc.
Amgen Inc.
Bayer Ag
Bristol-myers Squibb Co.
F. Hoffmann-la Roche Ltd.
Gilead Sciences Inc.
Gsk Plc.
Johnson & Johnson Services Inc.
Lilly
Pfizer Inc.
Sanofi
Swedish Orphan Biovitrum Ab
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings